<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379261</url>
  </required_header>
  <id_info>
    <org_study_id>CHILL-MI</org_study_id>
    <nct_id>NCT01379261</nct_id>
  </id_info>
  <brief_title>Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction</brief_title>
  <acronym>CHILL-MI</acronym>
  <official_title>Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment of patients suffering from&#xD;
      ST-elevation myocardial infarction (STEMI) with 1-2 liters of cold saline and central venous&#xD;
      catheter cooling with Philips InnerCool RTx Endovascular System prior to percutaneous&#xD;
      coronary intervention (PCI) result in a reduction in infarct size.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myocardial infarction (AMI) is the leading cause of mortality in the western world&#xD;
      today. Although reperfusion of the ischemic myocardium is a prerequisite for myocardial&#xD;
      salvage, it has been described that the reperfusion in itself may cause additional damage to&#xD;
      the myocardium (reperfusion injury). In the safety &amp; feasibility trial RAPID MI-ICE we&#xD;
      demonstrated that treatment of patients suffering from STEMI with 1-2 liters of cold saline&#xD;
      and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to&#xD;
      PCI was feasible, safe and resulted in a 38% reduction in infarct size/myocardium at risk.&#xD;
      The aim of the present study is to confirm this finding in a larger multicenter trial.&#xD;
&#xD;
      The study is a randomized, controlled, evaluator blinded, multicenter trial enrolling 120&#xD;
      patients at ten sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) assessed by cardiac MRI.</measure>
    <time_frame>At 4±2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) both assessed by cardiac MRI at 4±2 days in the patients who are cooled and achieve a target temperature of &lt; 35 C prior to PCI.</measure>
    <time_frame>At 4±2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) both assessed by cardiac MRI at 4±2 days in patients with an occluded and non-occluded IRA before PCI.</measure>
    <time_frame>At 4±2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) both assessed by cardiac MRI at 4±2 days in the per protocol population who are cooled according to protocol and meet inclusion criteria.</measure>
    <time_frame>At 4±2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) both assessed by cardiac MRI at 4±2 days in patients with anterior or inferior myocardial infarctions separately.</measure>
    <time_frame>At 4±2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of the hypothermia protocol on the incidence of death.</measure>
    <time_frame>45±15 days and 6 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level of high sensitivity Troponin T AUC through 48 hours and peak plasma level of high sensitivity Troponin T within 48 hours after AMI.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution 1.5 hour after opening the IRA.</measure>
    <time_frame>1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary blood flow and coronary angiography at the index event estimated by TIMI coronary flow and coronary perfusion grading.</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NT-proBNP levels at day 4±2.</measure>
    <time_frame>Day 4±2.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death at 1, 2, 3, 4 and 5 years.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size (as a percentage of myocardium at risk) assessed by cardiac MRI at 6±1 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of heart failure within 45±15 days.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pulmonary oedema.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleedings</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of the hypothermia protocol on the incidence of recurrent MI.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of the hypothermia protocol on the incidence of emergent stent revascularisation.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of the hypothermia protocol on the incidence of any hospitalisation.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Reperfusion Injury</condition>
  <condition>Anterior Wall Myocardial Infarction</condition>
  <condition>Inferior Wall Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Hypothermia treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cooling</intervention_name>
    <description>1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI</description>
    <arm_group_label>Hypothermia treatment</arm_group_label>
    <other_name>Hypothermia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical symptoms and signs of myocardial infarction and have a 12-lead ECG providing&#xD;
             evidence of an ongoing acute myocardial infarction, involving a large area of&#xD;
             myocardium, as defined by the following ECG criteria. The ECG changes should be&#xD;
             present upon arrival to the cath lab:&#xD;
&#xD;
               1. Anterior infarct: ST-segment elevation &gt;0.2mV measured 0.08 sec after the J point&#xD;
                  in 2 or more anatomically contiguous precordial leads, V1 through V4; and/or&#xD;
                  &gt;0.2mV in lead V5 V6.&#xD;
&#xD;
               2. Inferior infarct: ST elevation &gt;0.2mV measured 0.08 sec after the J point in 2 or&#xD;
                  more anatomically contiguous inferior leads, coupled with ST depression in 2&#xD;
                  contiguous anterior leads for a total ST deviation (inferior ST elevation plus&#xD;
                  anterior ST depression) of &gt;0.8mV.&#xD;
&#xD;
          2. Present to the study PCI lab within six (6) hours of the onset of acute cardiac&#xD;
             ischemic signs or symptoms (such as chest pain or pressure, arm or jaw pain, dyspnea,&#xD;
             nausea/vomiting, or syncope).&#xD;
&#xD;
          3. Be a candidate for PCI and have PCI planned as the immediate intervention.&#xD;
&#xD;
          4. Be willing and able to comply with study procedures, including returning for the MRI&#xD;
             scan at 4 ±2 days and be available for additional follow up Subject understands study&#xD;
             procedures and agrees to participate in the study by giving written informed consent.&#xD;
&#xD;
          5. Be in Killips Class I.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than eighteen (&lt;18) years of age&#xD;
&#xD;
          2. Age greater than or equal to eighty (80) years of age&#xD;
&#xD;
          3. Are pregnant.&#xD;
&#xD;
          4. Having an aortic dissection&#xD;
&#xD;
          5. History of a prior large myocardial infarct or an infarct in the same segment that is&#xD;
             currently affected.&#xD;
&#xD;
          6. Acute administration of a thrombolytic agent for the qualifying MI&#xD;
&#xD;
          7. Clinical suspicion of a non-thrombotic (e.g., pericarditis, vasospasm, takotsubo,&#xD;
             illicit drug use) cause for ST-segment elevation as determined by the investigator&#xD;
&#xD;
          8. If (during the screening process) the determination is made by site-study personnel&#xD;
             that initiation of cooling prior to diagnostic coronary angiography is technically not&#xD;
             feasible for any reason (should the patient be randomized to the Hypothermia Arm), the&#xD;
             prospective subject should not be enrolled.&#xD;
&#xD;
          9. Known risk for heparin induced thrombocytopenia (HIT)&#xD;
&#xD;
         10. Require an immediate surgical or procedural intervention other than PCI (e.g. CABG)&#xD;
&#xD;
         11. Present in cardiogenic shock or with end-stage cardiomyopathy&#xD;
&#xD;
         12. Have undergone at least ten (10) minutes of cardiopulmonary resuscitation (CPR) prior&#xD;
             to presentation to the PCI facility&#xD;
&#xD;
         13. History of surgical coronary artery revascularization (e.g. CABG)&#xD;
&#xD;
         14. Active bleeding, coagulopathy, or other contraindication to the placement of a&#xD;
             heparin-coated 14F central venous catheter via a 14F femoral venous introducer sheath&#xD;
             (e.g., known history of heparin induced thrombocytopenia, or IVC filter)&#xD;
&#xD;
         15. Contraindications to hypothermia&#xD;
&#xD;
         16. Personal or familial history of malignant hyperthermia&#xD;
&#xD;
         17. Known end-stage renal disease (ESRD; e.g., on dialysis, or status-post renal&#xD;
             transplant), known severe hepatic failure (e.g., cirrhosis, or acute hepatitis), or&#xD;
             any other contraindication to receiving meperidine (such as use of MAO inhibitors&#xD;
             within previous 14 days, history of seizures, history of hypersensitivity to&#xD;
             meperidine, etc.).&#xD;
&#xD;
         18. Serious concurrant medical condition likely to result in death during the next 12&#xD;
             months. Any other acute or chronic condition which the Investigator believes will&#xD;
             unacceptably increase the risk of study participation or interfere with study&#xD;
             procedures and assessments.&#xD;
&#xD;
         19. Contraindication to MRI (e.g., cardiac pacemaker, ICD, nerve stimulator, brain&#xD;
             aneurysm clips, cochlear implants, claustrophobia)&#xD;
&#xD;
         20. Deemed unsuitable by the investigators to participate in the study.&#xD;
&#xD;
         21. Active or recent (within 1 month prior to study enrollment) participation in another&#xD;
             investigational clinical research study.&#xD;
&#xD;
         22. Enrollment in or planned to be enrolled in another study of AMI therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Erlinge, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Skane University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Göran K Olivecrona, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Skane University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony Mullins</last_name>
    <role>Study Director</role>
    <affiliation>Philips Healthcare, San Diego, CA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Wallentin, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Uppsala University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Graz University Hospital</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital, Lund, Sweden</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Slovenia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>primary PCI</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Endovascular cooling</keyword>
  <keyword>Cardiac MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
    <mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Inferior Wall Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

